难治性类风湿关节炎的定义
生物制剂改善病情抗风湿药(bDMARDs)已改变类风湿关节炎(RA)结局,但部分患者对多种bDMARDs难治;难治性RA定义迄今任意,结局数据有限。本文讨论难治性RA的观点并提出准确识别难治队列的关键原则,包括证实多种治疗后持续炎症及承认抗药抗体产生,并总结潜在基础与未来评估建议。
要点
- 难治性RA定义迄今任意,结局数据及影响有限。
- 随机对照试验及部分真实数据提示约20%进展至第三种bDMARD,更少比例后续bDMARD失败。
- 识别难治队列需证实多种治疗后持续炎症并承认抗药抗体产生。
核心结论
- 难治性RA定义迄今任意,结局数据及影响有限,需专门研究以指导临床需求并为可靠探究潜在机制提供基础。
研究设计与样本
- 本文为观点文章,讨论难治性RA疾病观点并提出准确识别难治队列的关键原则。
主要发现
- 随机对照试验外推及部分真实数据提示约20%进展至第三种bDMARD,更少比例后续bDMARD失败。
关键数值与推荐
- 识别难治队列的关键原则包括证实多种治疗后持续炎症及承认抗药抗体产生。
临床怎么用
- 原文未据此给出推荐。
局限性
- 难治性RA定义迄今任意,结局数据及影响有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
While biologic disease-modifying antirheumatic drugs (bDMARDs) have transformed outcomes of people with rheumatoid arthritis (RA), a proportion of patients are refractory to multiple bDMARDs. Definitions of refractory RA thus far have been arbitrary, and outcome data and impact of such cohorts remain limited. Extrapolation from randomised controlled trial and some real-life data suggest approximately 20% progress onto a third bDMARD with a more modest proportion failing additional bDMARDs. This viewpoint discusses an opinion of refractory RA disease and proposes key principles to accurately identify refractory cohorts. These include demonstrating presence of persistent inflammation despite multiple therapies and acknowledging development of antidrug antibody. Potential basis of refractory disease is summarised, and suggestions for an initial approach in the future evaluation of refractory disease are offered. Specific investigation of refractory RA disease is necessary to inform the clinical need and provide a basis for robust investigation of underlying mechanisms.
引用
- Buch MH. Defining refractory rheumatoid arthritis. Ann Rheum Dis. 2018. PMID: 29588276. doi:10.1136/annrheumdis-2017-212862
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。